Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021

Apr 14, 2021 8:00am EDT

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

Mar 24, 2021 8:00am EDT

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Mar 01, 2021 8:00am EST

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Feb 16, 2021 8:00am EST

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

Feb 09, 2021 4:05pm EST

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Jan 15, 2021 4:10pm EST

Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease

Dec 07, 2020 8:00am EST

Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020

Nov 19, 2020 8:00am EST

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

Nov 11, 2020 4:10pm EST

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

Nov 11, 2020 7:30am EST